ScholarIQanswers from OpenAlex & ORCID
Manfred Kaufmann
ResearcherPublications, citations & collaboration network
Manfred Kaufmann is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Manfred Kaufmann have?
ScholarIQindexed works
Manfred Kaufmann has 229 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Manfred Kaufmann have?
ScholarIQcitation count
Manfred Kaufmann has 22,390 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Manfred Kaufmann?
ScholarIQh-index
Manfred Kaufmann has an h-index of 64 in OpenAlex.
What is the i10-index of Manfred Kaufmann?
ScholarIQi10-index
Manfred Kaufmann has an i10-index of 130 in OpenAlex.
What is the OpenAlex record for Manfred Kaufmann?
ScholarIQopenalex
The OpenAlex for Manfred Kaufmann is on the source record.
What are the most-cited papers on Manfred Kaufmann?
ScholarIQmost cited works
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
Gϋnter von Minckwitz, Michael Untch, Jens‐Uwe Blohmer, Serban Dan Costa, Holger Eidtmann, Peter A. Fasching, Bernd Gerber, W. Eiermann, J. Hilfrich, Jens Huober, Christian Jackisch, Manfred Kaufmann, Gottfried E. Konecny, Carsten Denkert, Valentina Nekljudova, Keyur Mehta, Sibylle Loibl
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
Ian Smith, Marion Procter, Richard D. Gelber, Sébastien Guillaume, A. Feyereislova, Mitch Dowsett, Aron Goldhirsch, Michael Untch, Gabriella Mariani, José Baselga, Manfred Kaufmann, David Cameron, Richard H. Bell, Jonas Bergh, Robert L. Coleman, Andrew Wardley, Nadia Harbeck, R.I. Lopez, Peter Mallmann, Karen A. Gelmon, Nicholas Wilcken, Erik Wist, Pedro Sánchez‐Rovira, Martine Piccart
A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors
Martin Filipits, Margaretha Rudas, R. Jakesz, Peter Dubsky, Florian Fitzal, Christian F. Singer, Otto Dietze, Richard Greil, Andrea Jelen, P. Sevelda, Christa Freibauer, Volkmar Müller, F. Jänicke, Marcus Schmidt, H. Kölbl, Achim Rody, Manfred Kaufmann, Werner Schroth, Hiltrud Brauch, Matthias Schwab, Péter Fritz, Karsten E. Weber, Inke Sabine Feder, Guido Hennig, Ralf Kronenwett, Mathias Gehrmann, Michael Gnant
Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update
Manfred Kaufmann, Gabriel N. Hortobágyi, Aron Goldhirsch, Suzy Scholl, Andreas Makris, Pinuccia Valagussa, Jens‐Uwe Blohmer, W. Eiermann, Raimund Jackesz, W. Jonat, Annette Lebeau, Sibylle Loibl, William R. Miller, Sigfried Seeber, Semiglazov Vf, Roy E. Smith, Rainer Souchon, Vered Stearns, Michael Untch, Gϋnter von Minckwitz
Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study
Michael Untch, Mahdi Rezai, Sibylle Loibl, Peter A. Fasching, Jens Huober, Hans Tesch, Ingo Bauerfeind, J. Hilfrich, Holger Eidtmann, Bernd Gerber, Claus Hanusch, Thorsten Kühn, Andreas du Bois, Jens‐Uwe Blohmer, Christoph Thomssen, Serban Dan Costa, Christian Jackisch, Manfred Kaufmann, Keyur Mehta, Gϋnter von Minckwitz